POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (8.3.2021, 5:30pm CEST, WHO):   U.S. 15,081    India 30,549    Brazil 20,503    Russia 22,010    France 1,996    The United Kingdom 21,687    Turkey 22,898    Argentina 6,083    Columbia 9,094    Spain 4,954    Italy 3,185    Iran 37,189    Germany 1,766    Indonesia 33,900    Mexico 6,740    South Africa 5,574    Peru 1,808    The Netherlands 2,136    Iraq 12,734    Philippines 8,167    Bangladesh 15,776    Malaysia 15,764    Pakistan 4,858    Portugal 1,190    Japan 8,877    Israel 1,326    Nepal 2,448    United Arab Emirates 1,537    Thailand 18,901    Morocco 4,206    Tunisia 1,243    Saudi Arabia 1,063    Georgia 4,827    Cuba 9,279    Myanmar 4,713    Ireland 1,352    Libya 2,892    South Korea 1,202    Algeria 1,358    Mongolia 1,019    Vietnam 7,832    Mozambique 1,421    Zimbabwe 1,309    Ghana 1,975    Réunion 3,014    Fiji 1,100    China 107    Singapore 111    New Zealand 1    Australia 229   

EMA starts rolling review of COVID-19 vaccine Vidprevtyn

Christian Fernsby |
EMA’s human medicines committee (CHMP) has started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur.

Article continues below




The CHMP’s decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.

EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorisation application.

EMA will assess the compliance of Vidprevtyn with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review.


What to read next

EMA starts rolling review of sotrovimab (VIR-7831) for COVID-19
EMA recommends COVID-19 Vaccine Moderna for authorisation in EU
Europe starts rolling review of Sputnik V COVID-19 vaccine